Compare GLP-1 and other weight-loss medicines
Compare GLP-1 and other weight-loss medicines using clinical trial results, dose information, side effects and country approval status. Clinical results and estimates are labelled separately. Use this tool to understand the evidence before discussing treatment with a qualified clinician.
Weight-loss medicines compared, using clinical-trial data
This tool compares medicines used for weight management by the average weight change seen in the supplied clinical-trial dataset, alongside how each is taken and whether it is approved in United Kingdom. Trial averages are not predictions: results and side effects vary from person to person, and a medicine that suits one person may not suit another. This page is information, not medical advice. Dataset date: August 2026 (supplied dataset; not independently reverified in this software update).
| Medicine | Active ingredient | Drug class | Average in trials | How it is taken | Approval |
|---|---|---|---|---|---|
| Mounjaro | tirzepatide | Dual GIP + GLP-1 agonist | −20.9% | Once-weekly injection (pre-filled pen) | Approved for weight management |
| Wegovy injection | semaglutide | GLP-1 receptor agonist | −18.7% | Once-weekly injection (pre-filled pen) | Approved for weight management |
| Wegovy pill | oral semaglutide 25 mg | GLP-1 receptor agonist | −13.6% | Daily tablet | Approved for weight management |
| Foundayo | orforglipron | GLP-1 receptor agonist (small molecule) | −11.2% | Daily tablet | Approved for weight management |
| Saxenda | liraglutide 3.0 mg | GLP-1 receptor agonist | −8.0% | Once-daily injection (pre-filled pen) | Approved for weight management |
| Mysimba | naltrexone / bupropion | Appetite + reward pathway (non-GLP-1) | −5.0% | Daily tablets (up to 2 twice daily) | Approved for weight management |
| Orlistat | orlistat | Gut lipase inhibitor (non-GLP-1) | −5.0% | Capsule with each main meal (up to 3×/day) | Approved for weight management |
Evidence & sources
Figures are drawn from peer-reviewed Phase 3 trials including SURMOUNT, STEP, OASIS-4, ATTAIN-1, TRIUMPH, SCALE, the COR programme, XENDOS, REDEFINE 1, PIONEER and CONQUER, together with regulator materials (MHRA, NICE, FDA, EMA). Some doses are estimated by interpolation between studied doses and are marked as estimates.
How to compare the figures
What does the GLP Med Compare Tool compare? Trial data, medicine type and country status.
The tool compares weight-loss medicines such as semaglutide, tirzepatide, liraglutide, orforglipron, retatrutide, CagriSema and other related treatments.
How should I read the figures? Direct results are stronger than estimates.
Some figures come directly from published or reported clinical trial results. Others may be estimated from nearby studied doses where no dose-specific trial result is available.
For example, if trial results exist for 5 mg and 10 mg, a 7.5 mg figure may be estimated between those doses. That can help with comparison, but it is not the same as a confirmed 7.5 mg trial result.
How do I compare results fairly? Study length, dose and patient groups matter.
Trial results are useful, but they are not always simple to compare. One study may run longer than another, use a different dose, or include people with different starting weights and health backgrounds.
Treat the figures as a guide to the evidence. They should not be read as a ranking, promise, shopping list or prediction of your own result.
Safety notes for upcoming medicines Trial attention does not mean legal availability.
New weight-loss medicines can attract attention long before they are approved. A trial result, press release or estimated dose comparison does not mean a medicine is available, legal to buy or safe to source online.
Frequently asked questions
What is the GLP Med Compare Tool? A quick explanation of the tool.
It is an educational Monj tool that compares GLP-1 and related weight-loss medicines using clinical trial data, estimated dose figures, treatment type and approval status by country.
Are all figures direct clinical trial results? No. Some may be estimates.
No. Some figures may come directly from clinical trials, while others may be estimated from nearby studied doses. Estimated figures should be treated as context only.
Does the tool tell me which medicine to take? No. It does not replace clinical advice.
No. The tool does not recommend treatment. It helps you understand the evidence before speaking to a qualified clinician or pharmacist.
Can trial averages predict my own result? No. Individual results vary.
No. Trial averages describe what happened across a study group. Your own result may be higher, lower or very different.
Why does the country selector matter? Approval and availability are local.
Medicine approval and availability are not the same everywhere. A medicine may be approved in one country, under review in another and unavailable somewhere else.
Page status: educational information only. Monj does not sell, prescribe or dispense medicines.
Dataset date: August 2026. The comparator uses a supplied clinical dataset. Nobody has independently reverified this dataset.
Clinical review: no independent clinical review has taken place. No clinician has reviewed this page or the dataset.
Page and software update: 5 October 2026. This update changed page text, layout and comparator display settings. The update did not check or validate the clinical data.
Author: Nick Johnson, Independent Prescription Pricing Analyst, Medstack Ltd.
Some dose figures are estimates from nearby clinical trial data. The tool labels these as estimates. Approval status and availability vary by country.